GASTROESOPHAGEAL ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Drug combo shows promise for tough cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: I-Mab Biopharma US Limited • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug combo shows promise for Hard-to-Treat GI cancers
Disease control CompletedThis study tested a new drug called zanidatamab (ZW25) combined with standard chemotherapy in 74 people with advanced HER2-positive cancers of the stomach, bile duct, or colon. The goal was to see if the combination is safe and shrinks tumors. Results will help decide if larger s…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 16:12 UTC